Clinical Research Partners
Advancing Toward a Cure for Lupus
Lupus Therapeutics collaborates with partners at clinical research institutions and companies in the biopharmaceutical industry to accelerate the development of safe and effective new therapies urgently needed by the lupus community.
The Lupus Clinical Investigators Network (LuCIN)
Lupus Therapeutics engages with more than 50 research medical centers and hundreds of lupus experts through the North America-based Lupus Clinical Investigators Network (LuCIN).
By partnering with and leveraging the experts within LuCIN and those impacted by lupus, Lupus Therapeutics strives to optimize engagement of key stakeholders and drive results in clinical development to extend the research continuum, to which LRA is dedicated, directly to patients.
Lupus Therapeutics is uniquely positioned to partner with the LuCIN centers to provide access to clinical trials for the lupus community while fostering collaboration with key stakeholders to accelerate and optimize the lupus clinical development process.
Current Collaborations and Initiatives
Lupus Therapeutics partners with biopharmaceutical companies throughout all phases of clinical research, from early clinical to post-marketing studies. A full suite of services is designed to help partners navigate all stages of clinical research—from pipeline prioritization to regulatory planning—to maximize their success.
Lupus Research Advisory & Consulting Services
Lupus Therapeutics delivers customized advisory services spanning drug development and clinical research, drawing upon the combined expertise of experts, Key Opinion Leaders, and individuals living with lupus.
- Medical/scientific advisory services are focused on evaluating and providing input on new treatment candidates, pipeline prioritization, clinical development plans, as well as making recommendations on study design, protocol development and operational feasibility.
- Patient advisory services allow for the incorporation of the patient voice, preferences, and needs into the treatment development process. Through activities such as a review of lupus portfolios and research priorities, input on study design and material development, the patient advisory services allow individuals living with lupus to be a research partner and enable the development of more patient-centric clinical research.
- Health equity advisory services specialize in evaluating and advising on study design and materials to enhance diversity, equity, and inclusion.
- Protocol Review Committee provides a way for industry to harness the expertise of LuCIN to inform lupus drug development by serving as an extramural review group comprised of LuCIN investigators.
Clinical Research Services
Lupus Therapeutics facilitates efficient study start-up and implementation for leading biotechnology and pharmaceutical companies conducting lupus clinical research.